Trial Profile
An observational study to describe the clinical impact (seizure freedom for 12 months) of clobazm (Frisium) as an adjunct therapy in patients who are not adequately stabilized with their anticonvulsant monotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2022
Price :
$35
*
At a glance
- Drugs Clobazam (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- Acronyms ADD ON
- Sponsors Sanofi
- 01 May 2022 Results of an analysis of one-year effectiveness of clobazam as an add-on therapy published in the Epilepsy and Behavior
- 22 Jun 2018 New trial record